Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1010475 | ENA |
REPOSITORIES: ENA
Similar Datasets
Project description:Transcriptional profiling of M.tuberculosis to 10 mM vitamin C at 8 h. This was compared to gene expression profile of untreated M. tuberculosis culture. Organism: Mycobacterium tuberculosis H37Rv, Genotypic Technology designed Custom Mycobacterium tuberculosis H37Rv Whole Genome 8x15k GE Microarray (AMADID-020181)
2014-10-01 | E-GEOD-60376 | biostudies-arrayexpress
Project description:This SuperSeries is composed of the following subset Series: GSE34919: Genome-wide Definition of the SigF Regulon in Mycobacterium tuberculosis (ChIP-chip) GSE34922: Genome-wide Definition of the SigF Regulon in Mycobacterium tuberculosis (Expression) Refer to individual Series
2012-01-20 | E-GEOD-35080 | biostudies-arrayexpress
Project description:We report the application of RNA sequencing to assess the expression dynamics of miRNAs and their isoforms over time upon infection with a panel of six intracellular bacteria (Mycobacterium tuberculosis H37Rv, Mycobacterium tuberculosis Beijing strain GC1237, Mycobacterium bovis BCG, Salmonella typhimurium strain Keller, Staphloccocus epidermidis and Yersinia pseudotuberculosis)
2015-02-18 | GSE64142 | GEO
Project description:Indepth proteomic profiling of Mycobacterium tuberculosis was performed fpr the purpose of genome annotation
2018-09-06 | PXD010956 | Pride
Project description:Beste2007 - Genome-scale metabolic network of
Mycobacterium tuberculosis (GSMN_TB)
This model is described in the article:
GSMN-TB: a web-based
genome-scale network model of Mycobacterium tuberculosis
metabolism.
Beste DJ, Hooper T, Stewart G, Bonde
B, Avignone-Rossa C, Bushell ME, Wheeler P, Klamt S, Kierzek AM,
McFadden J.
Genome Biol. 2007; 8(5): R89
Abstract:
BACKGROUND: An impediment to the rational development of
novel drugs against tuberculosis (TB) is a general paucity of
knowledge concerning the metabolism of Mycobacterium
tuberculosis, particularly during infection. Constraint-based
modeling provides a novel approach to investigating microbial
metabolism but has not yet been applied to genome-scale
modeling of M. tuberculosis. RESULTS: GSMN-TB, a genome-scale
metabolic model of M. tuberculosis, was constructed, consisting
of 849 unique reactions and 739 metabolites, and involving 726
genes. The model was calibrated by growing Mycobacterium bovis
bacille Calmette Guérin in continuous culture and
steady-state growth parameters were measured. Flux balance
analysis was used to calculate substrate consumption rates,
which were shown to correspond closely to experimentally
determined values. Predictions of gene essentiality were also
made by flux balance analysis simulation and were compared with
global mutagenesis data for M. tuberculosis grown in vitro. A
prediction accuracy of 78% was achieved. Known drug targets
were predicted to be essential by the model. The model
demonstrated a potential role for the enzyme isocitrate lyase
during the slow growth of mycobacteria, and this hypothesis was
experimentally verified. An interactive web-based version of
the model is available. CONCLUSION: The GSMN-TB model
successfully simulated many of the growth properties of M.
tuberculosis. The model provides a means to examine the
metabolic flexibility of bacteria and predict the phenotype of
mutants, and it highlights previously unexplored features of M.
tuberculosis metabolism.
This model is hosted on
BioModels Database
and identified by:
MODEL1507180021.
To cite BioModels Database, please use:
BioModels Database:
An enhanced, curated and annotated resource for published
quantitative kinetic models.
To the extent possible under law, all copyright and related or
neighbouring rights to this encoded model have been dedicated to
the public domain worldwide. Please refer to
CC0
Public Domain Dedication for more information.
2015-07-30 | MODEL1507180021 | BioModels
Project description:Transcriptional profiling of SirR and manganese regulated expression of genes in Mycobacterium tuberculosis strains comparing high manganese vs. low manganese in Rv (wild type Mycobacterium tuberculosis) and ST70 (mntR mutant strain of Mycobacterium tuberculosis)
2015-12-08 | GSE70812 | GEO
Project description:Transcriptional profiling of SirR and manganese regulated expression of genes in Mycobacterium tuberculosis strains comparing high manganese vs. low manganese in Rv (wild type Mycobacterium tuberculosis) and ST70 (mntR mutant strain of Mycobacterium tuberculosis) Two strains each with two conditions experiment, Rv (Mycobacterium tuberculosis wild type strain) high manganese vs. low manganese and ST70 (mntR mutant strain of Mycobacterium tuberculosis) high manganese vs. low manganese. Number of biological replicates is 3 for each condition for each strain.
2015-12-08 | E-GEOD-70812 | biostudies-arrayexpress
Project description:①Background:Tuberculosis is mainly a respiratory tract infection caused by mycobacterium tuberculosis and one of the leading causes of death worldwide. According to the Global Tuberculosis Report in 2021, About a quarter of the world's population is infected with Mycobacterium tuberculosis and China is the second highest burden of TB. Although TB diagnosis and prevention techniques have become more mature, the number of TB cases is still increasing, mainly due to: the prevalence of drug-resistant tuberculosis bacteria, tuberculosis and HIV co-infection, long incubation time of mycobacterium tuberculosis difficult to early diagnosis and so on. Therefore, it is of great significance to study the pathogenesis of mycobacterium tuberculosis infection.②Method: THP-1 cells were treated with 50ng/ml PMA for 24 hours, so that THP-1 cell can be induced into macrophages. After that THP-1 macrophages were infected with mycobacterium tuberculosis H37Rv(MOI=1), which were collected and applied to RNA-sequencing. The constructed sequencing library was sequenced using an Illumina Novaseq 6000 system.
2022-08-31 | GSE203261 | GEO
Project description:Investigation of whole genome gene expression level changes in Mycobacterium tuberculosis treated with the DHFR inhibitor WR99210, compared to untreated cells. The antimycobacterial properties of WR99210 are further described in Gerum, A., Ulmer, J., Jacobus, D., Jensen, N., Sherman, D., and C. Sibley. 2002. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase. Antimicrob Agents Chemother 46(11):3362-3369 [PMID:12384337]
2012-09-18 | GSE40917 | GEO
Project description:Currently available model organisms such as Mycobacterium smegmatis and Mycobacterium bovis Bacillus Calmette-Guérin (BCG) have significantly contributed to our understanding of tuberculosis (TB) biology, these models have limitations such as differences in genome size, growth rates and virulence. Attenuated Mycobacterium tuberculosis strains may provide more representative, safer models to study M. tuberculosis biology. For example, the M. tuberculosis ΔleuDΔpanCD double auxotroph, has undergone rigorous in vitro and in vivo safety testing. Like other auxotrophic strains, this has subsequently been approved for use in biosafety level (BSL) 2 facilities. Auxotrophic strains have been assessed as models for drug-resistant M. tuberculosis and for studying latent TB. These offer the potential as safe and useful models, but it is important to understand how well these recapitulate salient features of non-attenuated M. tuberculosis. We therefore performed a comprehensive comparison of M. tuberculosis H37Rv and M. tuberculosis ΔleuDΔpanCD. These strains demonstrated similar in vitro and intra-macrophage replication rates, similar responses to anti-TB agents and whole genome sequence conservation. Shotgun proteomics analysis suggested that M. tuberculosis ΔleuDΔpanCD has an increased propensity to enter a dormant state during acid stress, which has been verified using a dual-fluorescent replication reporter assay. Importantly, infection of human peripheral blood mononuclear cells with the 2 strains elicited comparable cytokine production, demonstrating the suitability of M. tuberculosis ΔleuDΔpanCD for immunological assays. We provide comprehensive evidence to support the judicious use of M. tuberculosis ΔleuDΔpanCD as a safe and suitable model organism for M. tuberculosis research, without the need for a BSL3 facility.
2019-07-30 | PXD013677 | Pride